A New Drug Shows Promise of Hepatitis C Cure
March 29, 2013
Researchers report success in blocking the hepatitis C virus's ability to colonize liver cells in 18 hepatitis C-infected patients with five weeks of treatment using the antisense oligonucleotide miravirsen. Fourteen weeks after miravirsen injections ended, hepatitis C viral loads were still undetectable in 5 of 18 patients.
Miravirsen binds tightly to messenger proteins of liver cells and blocks the hepatitis C virus from colonizing the proteins, which the virus needs to survive and replicate. Without a foothold in liver cells, the hepatitis C virus does not have the chance to develop resistance to protease inhibitors such as teleprevir and boceprivir. As a result, hepatitis C patients could be able to stop taking interferon and ribavirin, which cause side effects likeView Full Article
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)